CTOs on the Move

NanoHybrids

www.nanohybrids.net

 
NanoHybrids specializes in research and commercialization of nanotechnology-based products that enhance diagnosis and therapy for cancer and other diseases through enhanced molecular imaging and profiling. Our molecular imaging nanoparticles enhance contrast in vitro and in vivo across multiple biomedical imaging modalities. We are the leading provider of silica-coated gold nanoparticles optimized for photoacoustic (optoacoustic) imaging. With conjugation services we provide nanoparticles with high specificity for targeted cell receptors and tailored to individual applications. Our nanoparticles improve signal strength and allow real time imaging of functional biology. Interested in learning how we are using nanotechnology to drive advances in the life-sciences? ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Justin Harris
 Chief Technology Officer Profile

Similar Companies

Moximed

If you suffer from chronic pain or aching in your knee, you may have osteoarthritis (OA) – a painful joint condition that can interfere with nearly all aspects of daily life. Right now, doctors at select centers in the U.S. are accepting participants for the Atlas Clinical Trial. The trial is for the Atlas System – an investigational device designed to relieve knee pain, while preserving your joint’s natural anatomy and motion.

Union Supplier Of America Inc

Union Supplier Of America Inc is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brown and Toland Physicians Services Organization

Brown and Toland Physicians Services Organization is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Helix Medical Communications

Helix Medical Communications is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyrano Therapeutics

The Cyrano team has developed a unique, proprietary intranasal product to restore function in patients with a chronic loss of taste and smell. This is a condition affecting at least 14 million people in the US and a similar number in Europe, having a significant impact on safety, quality of life and well-being.